C2N Diagnostics
St. Louis-based C2N Diagnostics, LLC is a private firm specializing in protein diagnostic and therapeutic discovery.
Founded
2007St. Louis-based C2N Diagnostics, LLC is a private firm specializing in protein diagnostic and therapeutic discovery.
Founded in St. Louis, C2N Diagnostics, LLC is a private company dedicated to advancing protein diagnostic and therapeutic discovery. Its core mission is to develop and commercialize novel diagnostics for Alzheimer’s disease and related neurodegenerative conditions to enhance treatment decisions and improve patient outcomes. The company offers state-of-the-art blood tests, including the PrecivityAD® and PrecivityAD2™ tests, which utilize proprietary liquid-chromatography-tandem mass spectrometry (LC-MS) methodologies to assess brain amyloid pathology.
C2N Diagnostics boasts a team of leading neurological scientists and researchers. Notable investors and affiliated individuals include prominent figures in the biotechnology and healthcare sectors. The company's key achievements include the successful development and commercialization of its Precivity™ tests, which have significantly impacted the early detection and management of Alzheimer’s disease. Through its innovative diagnostic solutions, C2N Diagnostics has made substantial contributions to the field of neurodegenerative disease research and patient care.
Companies similar to C2N Diagnostics include Celestia Diagnostics, Test Diagnostics, Plasmonic Diagnostics and Cx Precision Medicine.
C2N Diagnostics was founded in 2007.
C2N Diagnostics' headquarters is located in St. Louis, MO, US.
C2N Diagnostics' most recent funding round was for $15M (USD) in February 2023.
As of Feb 16, 2023, C2N Diagnostics has raised a total of $37.2M (USD).
C2N Diagnostics has 62 employees as of Feb 4, 2024.
